Fig. 3From: Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trialCytokines and chemokines. GeoMean geometric mean. No adjustments for multiplicity were madeBack to article page